Assignee
ARVINAS OPERATIONS INC
US·59 granted patents·55 pending applications·135 citations·filing 2017–2025
Top patents by PatentIndex Score
114 records- 0198US11883393B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Jan 30, 2024·5 cites·4 claims
- 0298US11236051B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Feb 1, 2022·9 cites·3 claims
- 0398US11104666B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Aug 31, 2021·18 cites·15 claims
- 0498US10899742B1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Jan 26, 2021·18 cites·25 claims
- 0598US10844021B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2019·Granted Nov 24, 2020·13 cites·25 claims
- 0697US11952347B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2021·Granted Apr 9, 2024·3 cites·7 claims
- 0797US11597720B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Mar 7, 2023·4 cites·48 claims
- 0895US12077509B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2023·Granted Sep 3, 2024·1 cites·4 claims
- 0995US12053469B2Indazole based compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2021·Granted Aug 6, 2024·6 cites·6 claims
- 1095US11981683B2Indazole based compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2022·Granted May 14, 2024·5 cites·2 claims
- 1192US11964945B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Apr 23, 2024·2 cites·26 claims
- 1292US11173211B2Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptidesARVINAS OPERATIONS INC·Filed 2019·Granted Nov 16, 2021·6 cites·25 claims
- 1392US11065231B2Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptidesARVINAS OPERATIONS INC·Filed 2018·Granted Jul 20, 2021·16 cites·24 claims
- 1491US12036209B2Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptidesARVINAS OPERATIONS INC·Filed 2021·Granted Jul 16, 2024·2 cites·3 claims
- 1591US11384063B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2020·Granted Jul 12, 2022·2 cites·8 claims
- 1690US11858940B2Selective modulators of mutant LRRK2 proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2021·Granted Jan 2, 2024·2 cites·12 claims
- 1790US2025320195A1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 1889US11986532B2Modulators of BCL6 proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2022·Granted May 21, 2024·1 cites·4 claims
- 1989US11191741B2Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptideARVINAS OPERATIONS INC·Filed 2017·Granted Dec 7, 2021·3 cites·13 claims
- 2089US11161841B2Modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2019·Granted Nov 2, 2021·3 cites·22 claims
- 2189US2025034096A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 2287US12043612B2Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the sameARVINAS OPERATIONS INC·Filed 2021·Granted Jul 23, 2024·3 cites·12 claims
- 2387US11912699B2Tau-protein targeting compounds and associatedARVINAS OPERATIONS INC·Filed 2020·Granted Feb 27, 2024·2 cites·21 claims
- 2486US10994015B2EGFR proteolysis targeting chimeric molecules and associated methods of useARVINAS OPERATIONS INC·Filed 2017·Granted May 4, 2021·3 cites·25 claims
- 2585US12427144B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2023·Granted Sep 30, 2025·0 cites·16 claims
- 2685US11707452B2Modulators of alpha-synuclein proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2019·Granted Jul 25, 2023·2 cites·19 claims
- 2785US11427548B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2019·Granted Aug 30, 2022·2 cites·15 claims
- 2885US2025228944A1Compounds and methods for the targeted degradation of bromodomain-containing proteinsARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 2984US12156916B2Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2023·Granted Dec 3, 2024·0 cites·9 claims
- 3084US11957759B1Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2023·Granted Apr 16, 2024·0 cites·6 claims
- 3184US11512083B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2020·Granted Nov 29, 2022·1 cites·17 claims
- 3284US2024076281A1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
- 3383US2026053796A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 3482US2025223265A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 3581US10865202B2Indole derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2019·Granted Dec 15, 2020·1 cites·20 claims
- 3681US2025161465A1Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 3780US12171831B2Compounds and methods for the targeted degradation of bromodomain- containing proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Dec 24, 2024·0 cites·14 claims
- 3879US12441708B2Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2022·Granted Oct 14, 2025·0 cites·20 claims
- 3979US12239711B2Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2022·Granted Mar 4, 2025·0 cites·1 claims
- 4079US2024382599A1Egfr proteolysis targeting chimeric molecules and associated methods of useARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 4178US12264157B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Apr 1, 2025·0 cites·24 claims
- 4278US12172981B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2021·Granted Dec 24, 2024·0 cites·18 claims
- 4378US10806737B2Compounds and methods for the targeted degradation of fetal liver kinase polypeptidesARVINAS OPERATIONS INC·Filed 2017·Granted Oct 20, 2020·2 cites·23 claims
- 4478US2025313547A1Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 4578US2026022117A1Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 4677US2025360219A1Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 4776US2024059686A1Compounds and methods for the targeted degradation of the androgen receptorARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
- 4875US12559506B2Indazole based compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2024·Granted Feb 24, 2026·0 cites·20 claims
- 4974US12496301B2Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophyARVINAS OPERATIONS INC·Filed 2024·Granted Dec 16, 2025·0 cites·30 claims
- 5074US2024299366A1Imide-based modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 114 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →